Integrated ReportFiscal Year Ended Mar. 31, 2019
Philosophy
Overview
- At a Glance
- Our Innovation History—100 Years of Olympus
- Products and Market Share in the Medical Field
Strategy
Business
- Message from the COO
- Expansion of Growing Businesses in Asia
- Stronger Reprocessing Initiatives to Improve the Safety of Medical Devices
- Endoscopic Solutions Division
- Therapeutic Solutions Division
- Scientific Solutions Division
- Imaging Division
Innovation
- Message from the CTO
- R&D Activities and Intellectual Property Activities
- Partner and Customer Assets
ESG
- Message from the CAO
- Human Resources
- Employee Roundtable Discussion―Discussion about Olympus’ Corporate Culture
- Environment
- Message from Outside Directors
- Olympus’ Corporate Governance
- Compliance
- Risk Management
- Directors
Facts
- Financial / Non-Financial Highlights
- 10-Year Financial / Non-Financial Data
- Risk Information
- Consolidated Financial Statements and Notes
- Independent Auditor’s Report
- Olympus Group Companies
- Corporate Information / Stock Information
- FY Ended Mar. 31, 2025
- FY Ended Mar. 31, 2024
- FY Ended Mar. 31, 2023
- FY Ended Mar. 31, 2022
- FY Ended Mar. 31, 2021
- FY Ended Mar. 31, 2020
- FY Ended Mar. 31, 2019
- FY Ended Mar. 31, 2018
- FY Ended Mar. 31, 2017
- FY Ended Mar. 31, 2016
- FY Ended Mar. 31, 2015
- FY Ended Mar. 31, 2014
- FY Ended Mar. 31, 2013
- FY Ended Mar. 31, 2012
Detailed social report and environmental activities are included in the CSR data book
CSR Data Book